DXSE:F:F-Xtrackers Stoxx Europe 600 Health Care Swap UCITS ETF 1C (EUR)

ETF | Others |

Last Closing

USD 218.5

Change

-3.05 (-1.38)%

Market Cap

N/A

Volume

N/A

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-01-13 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
PRAJ:F Amundi Index Solutions - Amund..

-0.09 (-0.31%)

USD 139.20B
UIM5:F UBS (Lux) Fund Solutions - MSC..

-0.21 (-0.41%)

USD 114.13B
SXR8:F iShares Core S&P 500 UCITS ETF..

+0.28 (+0.05%)

USD 106.46B
ZPDJ:F SPDR® MSCI Japan UCITS ETF

N/A

USD 100.12B
XDNY:F Xtrackers MSCI Japan ESG Scree..

-0.06 (-0.40%)

USD 63.18B
VUSA:F Vanguard Funds Public Limited ..

-0.61 (-0.56%)

USD 51.63B
VUAA:F Vanguard S&P 500 UCITS Acc

-0.98 (-0.90%)

USD 51.63B
SXRZ:F iShares VII PLC - iShares Nikk..

-0.80 (-0.33%)

USD 51.11B
XJSE:F Xtrackers II - Japan Governmen..

+0.06 (+0.77%)

USD 43.12B
0ZC:F Zscaler Inc

+2.50 (+1.39%)

USD 37.92B

ETFs Containing DXSE:F

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 1.72% 79% B- 65% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 1.72% 79% B- 65% D
Trailing 12 Months  
Capital Gain 2.90% 34% F 50% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 2.90% 30% F 42% F
Trailing 5 Years  
Capital Gain 33.39% 64% D 65% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 33.39% 64% D 48% F
Average Annual (5 Year Horizon)  
Capital Gain 9.74% 68% D+ 65% D
Dividend Return 9.74% 66% D+ 57% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 8.61% 73% C 93% A
Risk Adjusted Return 113.07% 97% N/A 97% N/A
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:

There is nothing we particularly dislike